.png?width=600&height=360&name=Discovery%20%26%20Development%20Europe%202025%20(Light%20Version).png "Discovery & Development Europe 2025 (Light Version)")
Andreas Gryczke
Director, Process Engineering,
AbbVie
Davide Gianni
Senior Director,
AstraZeneca
Heinrich Haas
Chief Technology Officer,
Neovacs
Kate Humphrey
Chief Scientific Officer, Oxford Drug Discovery Institute,
Moffitt Cancer Center
Morten Grunnet
Vice President, Head of Neuroscience,
Lundbeck
Philippe Marc
Executive Director, Global Head of Integrated Data Sciences,
Novartis
Rekha Lakshmanan
Global Head of Data Office,
AstraZeneca
Shadi Farhangrazi
Chief Executive Officer,
S.M. Discovery Group
Sorina Morar-Mitrica
Director Science & Technology,
Novartis
Stephen Pham
Senior Vice President, Product Development,
Avalyn Pharma Inc.
Ulrich Betz
Vice President Innovation,
Merck
Vineeta Tripathi
Chief Executive Officer,
Vitarka Therapeutics
Aaron Smith
Associate Director Oncology DMPK,
AstraZeneca
Abhishek Choudhary
Principal Data Engineer,
Bayer
Abi Heath
Patent Attorney & Counsel,
Kilburn & Strode
Alain Martelli
Director External Science and Innovation, France,
Pfizer
Alexander Natz
Secretary General,
EUCOPE
Amal Ali Elkordy
Professor,
University of Sunderland
Andreas Bernkop Schnurch
Professor,
University of Innsbruck
Andrew Woodhead
Head of Chemistry,
Astex Pharmaceuticals
Andrew Ledgard
Senior Scientist,
Recursion
Andy Pike
Senior DMPK Discovery and Development Lead, Director,
AstraZeneca
Anna-Pia Papageorgiou
Policy Officer, Health Innovations & Ecosystems, DG Research & Innovation,
European Commission
Antonia Stepan
Section Head, Medicinal Chemistry,
Roche
Schedl_quantro-tx.jpg?length=600&name=1a7420d5-7d72-4600-b14a-ead67fd7791c-2-11764368speaker_photo-039_20220601_(c)Schedl_quantro-tx.jpg)
Arianna Sabò
Head of Research & Discovery,
QUANTRO Therapeutics
Arne Skerra
Professor,
Technische Universität München
Benedict Cross
CTO,
PhoreMost Ltd
Bobby Soni
CIO,
BioInnovation Institute
Burkhard Schäfer
Managing Director & Director at SiLA,
SiLA
Christine Maurer
Scientific Associate Director Biotransformation,
Merck & Cie KmG
Christoph Rösli
Director Research,
CSL Behring & BaseLaunch
Chuang Kee Ong
Director Data Product,
GSK
Covadonga Paneda
Chief Operating Officer,
Altamira Therapeutics
Dan Hardy
Chief Executive Officer,
Microsol Science
Daniel Tondera
Head of Biology,
Pantherna Therapeutics
David Jenkinson
Head of Childhood Cancer Translational Challenge,
LifeArc
David Dexter
Research Director,
Parkinson's UK
David Gnutt
Vice President, Complex In Vitro Lead, RED Cardiovascular, Renal and Immunology,,
Bayer
Diana Knapp-Bühle
Associate Director and DMPK Lead,
Merck Healthcare KGaA
Doris Roth
Lab Head HTS,
F. Hoffmann-La Roche Ltd.
Duane Schulthess
CEO,
Vital Transformation
Eric Lorent
Senior Scientist,
Sanofi
Estelle Beguin
Director Technology Research,
Ethris
Fabrizio Dissegna
Formulator,
Chiesi
Farshad Ramazani
Senior Expert Science & Technology,
Novartis Pharma
Florian Ries
Senior Scientist II,
AbbVie
Giovanna Lalli
Director, Strategy & Operations,
LifeArc
Giovanni Spagnolli
Chief Technology Officer,
Sibylla Biotech
Giovanni Ca'Zorzi
Strategic Communications,
Cohesion Bureau
Heena Khatter
Principal Scientist,
Roche
Helen Bright
Chief Scientific Officer,
Centauri Therapeutics
Hemachandran Kannan
Director of the AI Centre,
Woxsen University
Ian Roberts
Director of Therapeutic Technology,
Healx
Jack Doolan
Investigator,
GSK
James Dale
Director of Drug Discovery,
PharmEnable Therapeutics
James Love
Vice President, Automation and Process Optimization,
Novo Nordisk
James Connell
Scientific Director - Translational Matrix Group,
LifeArc
Jens Twellmeyer
Associate Director Science & Technology,
Novartis AG
Jessica Yu
Senior Scientist,
AstraZeneca
Joao Seixas
CEO,
TargTex
Joel Richard
Chief Development Officer,
Enterome
Jonathan Hopper
Vice President, Platforms & Founder,
OMass Therapeutics
Jörg Berghausen
Associate Director,
Novartis
Jose-Carlos Gomez-Tamayo
Scientist,
Janssen Pharmaceutical Companies of Johnson & Johnson
Kamalinder Kaur Singh
Professor of Pharmaceutical Technology and drug delivery,
https://www.uclan.ac.uk/?msclkid=75cded44b4e311ecbaf6958f72df03d3
Karin Conde-Knape
Senior Vice President Global Drug Discovery,
Novo Nordisk
Karsten Maeder
Professor,
Martin Luther University Halle-Wittenberg
Katarzyna Malik
R&D Director,
Polpharma
Kelly Zalocusky
Senior Director of Computational Biology, Neuroscience,
Recursion Pharmaceuticals
Knut Biber
Research Fellow & Head of Glial Biology Team,
AbbVie
Konstantinos Gkatzis
Cardiovascular Team Lead & COO at Myrtil Biotechnologies,
Ksilink
Kristina Levan
Business Developer,
Business Region Gothenburg
Krisztian Kaszas
Sr Scientist, Assay Automation,
Johnson & Johnson
Lars van der Veen
Chief Scientific Officer,
ionctura
Laura Gasparini
Director -Tau pathobiology,
AbbVie
Lene Gerlach
Venture Partner, Founder of Women in Life Science Denmark (WiLD),
Hadean Ventures
Lubor Gaal
Chief Financial Officer & Chief Business Officer,
Circio
Maeve Caldwell
Professor in Neuroscience, Physiology,
Trinity College Dublin
Manuela Cerina
Scientific Director of Neurodegeneration,
LifeArc
Maria Levitin
Director of RNA Oligonucleotide Delivery, Genetic Medicine,
Grünenthal GmbH
Marius Lutz
Scientist, High-Throughput Experimentation, Chemical Reaction Screening,
Hoffmann La Roche Ltd
Martinus Capelle
Scientific Director,
Johnson & Johnson
Meike Harms
Lead Scientist,
Merck KGaA
Meiling Li
Technical project leader,
F.Hoffmann-La Roche
Michael Johnson
Professor of Neurology and Genomic Medicine,
Imperial College London
Miroslav Cik
Senior Principal Research Scientist,
Abbvie
Moein Moghimi
Professor of Nanomedicine and Pharmaceutics, School of Pharmacy,
Newcastle University
Naisha Shah
Vice President of Data Science,
BioAge Labs
Natasha Drapeau
Managing Director & Co-Founding Senior Partner, Cohesion Bureau,
Cohesion Bureau
Paulina Kolasinska-Zwierz
Principal Scientist,
Alchemab
Peng Leong
CBO and Head of Brain Aging,
Bioage labs
Phil Noble
Head of Single B Cell Antibody Discovery,
UCB Pharma
Philip Hewitt
Global Head of Early Investigative Toxicology,
Merck
Poppy Winlow
Senior Research Scientist,
AstraZeneca
Rainer Wilcken
Director, Computational Chemistry,
Flare Therapeutics Inc
Rajaa Sukhun
Senior Director of Research DMPK,
Cytokinetics
Ramesh Kashi
Senior Scientific Advisor,
EPOK Therapeutics
Rick Ewing
VP, Head of Chemistry,
Rapafusyn Pharmaceuticals
Robin Loving
Chief Scientific Officer,
Salipro Biotech AB
Roderick Beijersbergen
Head of NKI Genomics Core Facility & Professor of Functional Genomics,
The Netherlands Cancer Institute
Sabine Kuratli
CMC Lead,
CEPI
Sagar Chandekar
Global Medical Manager- Neurodegenerative Diseases,
Novo Nordisk
Saif Shubber
Associate Director,
Bicycle Therapeutics
Sandor Batkai
Freelance Consultant,
Batkai.Condulting (ex-Cardior Pharmaceuticals)
Sarah Jolly
Principal Scientist,
LifeArc
Shayoni Dutta
Data Science Manager,
GLAXOSMITHKLINE
Shilpa Thosar
Ex Director,
Cara Therapeutics
Shreenivasa Rajanala
VP, Global Head of Data Science and Advanced Analytics,
Bayer
Simone Vecchi
Associate Director - Drug Product Development Scientific Integrator,
Johnson & Johnson Innovative Medicine
Simone Hornemann
Director UZH CRISPR Screening Hub,
University Hospital Zurich
Sonja Kühn
Head of Structural Biophysics and Computational Chemistry PA, Research,
LES LABORATOIRES SERVIER
Sophie Janbon
Director,
AstraZeneca
Steen Krogsgaard
Scientific Automation Director,
Novo Nordisk
Stefan Schiesser
Director of Medicinal Chemistry,
AstraZeneca
Stephanie Harlfinger
Senior Director, Global Head NCE DMPK,
Merck & Cie KmG
Supriyadi Hafiz
Senior Scientist,
Merck
Suruchi Vishwasrao
Senior Scientist,
Merck Life Science Pvt. Ltd.
Sven Verguts
Associate Director, Emerging Biotech & ATMPs,
Merck
Tamara Maes
Former Chief Scientific Officer & Founder,
Oryzon Genomics
Tanvir Tabish
Director, Early Formulation Development,
Boehringer Ingelheim RCV GmbH & Co KG
Thanneer Malai Perumal
Senior Principal Scientist,
Hoffmann La Roche Ltd
Thomas Von Erlach
Chief Scientific Officer,
Vivtex
Tjasa Vrlinic
PI,
Medincell
Tom Kissling
pRED Automation Partner & Director at SiLA,
F. Hoffmann-La Roche AG
Toria Legh-Land
Computational Pharmaceutics Lead,
Microsol
Trond Ulven
Professor,
Copenhagen University
Valentina Romeo
Principal Scientist & Group Leader,
Roche
Varun Kushwah
Principal Scientist,
RCPE
Vik Reebye
Head of Academic Partnership,
MiNA Therapeutics Ltd
Virginia Ballotta
New Ventures Manager,
BaseLaunch
Vladimir Talibov
Associate Principal Scientist,
Sprint Bioscience
Yi Sun
Associate Professor,
Technical University of Denmark
Zeeshan Ahmad
Reader in Pharmaceutics and Drug Delivery,
De Monfort University
Zhi Yao
Principal Scientist,
LifeArc
Zoran Rankovic
Professor of Chemical Biology, and Director of the Centre for Protein Degradation,
The Institute of Cancer Research
Meet Our Esteemed Sponsors
Platinum Sponsors
XtalPi
Platinum Sponsor
XtalPi is an innovative research platform company powered by artificial intelligence (AI) and robotics. Established in 2015 by three postdoctoral physicists at MIT, XtalPi is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. XtalPi combines quantum physics, AI, cloud computing, and large-scale robotics to provide R&D solutions, services, and products for pharmaceuticals, biotechnology, renewable energy, and advanced materials industries globally.
Gold Sponsors
BioDuro-Sundia
Gold Sponsor
BioDuro is a US company founded in 1996, and headquartered in Irvine, California. With more than 2,000+ scientists, we have 7 R&D and manufacturing campuses across the US and China. We offer fully integrated CRDMO services from discovery to commercial manufacturing across medicinal chemistry, biology, DMPK, drug substance and drug product, including multiple modalities small molecules, peptides, oligonucleotides and antibody drug conjugates. We leverage our broad capabilities and unique technology platforms to empower biotech and pharmaceutical partners worldwide. Our integrated approaches accelerate and de-risk new drug discovery and development, creating higher value outcomes for our clients. Committed to the highest standards of compliance and business operations, we maintain a science-driven, customer-oriented, innovative and people-focused culture. As a pure-play CRDMO, BioDuro operates under one global standard, providing integrated, fast, and flexible services to meet the unique needs of our clients and accelerate development timelines.
Silver Sponsors
Axxam
Silver Sponsor
Axxam provides integrated early discovery services and solutions across the life sciences industry. We support pharmaceutical and biotech companies, start-ups, patient foundations, and academic groups in their journey from target assessment to lead optimization across all therapeutic areas and target classes. Axxam’s services comprise assay development, hit identification, including high-throughput screening, and hit-to-lead activities.
IRBM
Silver Sponsor
IRBM is a scientific contract research organization (CRO) that stands at the forefront of drug discovery, leveraging a single, unified research facility to accelerate team-based breakthroughs and improve efficiencies from concept to candidate. With a history of contributing to several approved drugs, and its own internal pipeline of oncology and other therapeutic assets, IRBM is powered by deep collaborations and decades of expertise from leading global institutions. Their comprehensive in-house capabilities assist partners in achieving key milestones and progressing towards clinical readiness, positioning IRBM as a major player in driving innovation in the pharmaceutical and biotech fields. For further information, please contact us: bd@irbm.com Website: https://www.irbm.com/
NanoFCM
Silver Sponsor
NanoFCM provides a versatile and powerful platform - Flow NanoAnalyzer for the multiparameter analysis of functional nanoparticles (7-500 nm) at single-particle level which has the capacity to measure the size, concentration, and biological properties of nanoparticles. To our knowledge, Flow NanoAnalyzer is the only flow cytometry instrument that covers the size range of exosomes (30-120 nm). Flow NanoAnalyzer is expected to become a powerful tool for life science, nanoscience and nanotechnology studies. Flow NanoAnalyzer can be used for the characterization of extracellular vesicles(EVs), viruses, bacteria, and other natural biological nanoparticles as well as functional nanoparticles, which opens up a window to the nano-world for flow technology. By means of high-selectivity, high-resolution and high-throughput detection of the particle size, concentration, and biochemical properties of a single nanoparticles (7-1000 nm).
Pivot Park Screening Centre
Silver Sponsor
Pivot Park Screening Centre is a Dutch company that offers services in assay development, lab automation, ultra-High Throughput Screening (uHTS), High Content Screening and hit-to-lead profiling, in order to find novel hits for drug development. We develop and miniaturize high-quality cellular, biochemical and biophysical primary, deselection, orthogonal and selectivity assays across various target classes and disease areas, and have carried out over 250 full-deck uHTS campaigns across libraries ranging ~0.3-1.5 million compounds, using label-based and label-free (MALDI-MS) readouts, mostly in 1,536-well plate format. You can either bring your own compound library or use our 300K IP-free druglike compound library.
Bronze Sponsors
.jpg?length=600&name=3d0c22d6-b4ef-4e05-be3b-05fbfbf42619-2-5668375logo-CDDV_L_BLUE_ON_BLUE_SHAD_CMYK-(10).jpg)
InnoCore Pharmaceuticals
Bronze Sponsor
InnoCore Pharmaceuticals is a biopharmaceutical drug delivery company specialized in the development of long acting and minimally invasive drug delivery products for the treatment of several (chronic) diseases e.g. oncology, pain, atherosclerosis, macular degeneration, CV, osteoarthritis. Our company is using a biodegradable polymer based platform for complex injectables by making microspheres, in-situ-forming depo's and implant formulations. We support the formulation of small molecules, peptides and proteins (including antibodies) for controlled release delivery from days up to six months.
Network & Programme Sponsors
Ardigen S.A
Network & Programme Sponsor
Ardigen is a leading AI Contract Research Organisation (CRO) dedicated to increasing the success rate of drug discovery. Recognized among the top 5% of AI in drug discovery companies worldwide, Ardigen integrates expertise in biology, bioinformatics, machine learning, and software engineering to deliver advanced computational solutions exclusively tailored for the biotechnology and pharmaceutical sectors. Over the past 10 years, we have earned the trust of over 120 clients, including 15 major pharmaceutical companies, by providing exceptional in silico research and data engineering services.
.jpg?length=600&name=c8f3ee46-970d-4da4-984f-fe6394fe9ac0-2-5668375logo-Glatt_PS_Mailchimp-header_schmaler-(1).jpg)
Glatt Pharmaceutical Services
Network & Programme Sponsor
Glatt Pharmaceutical Services offers solutions for formulation and process development of solid dosage forms. Scale up, Clinical trials materials and commercial manufacturing from our sites in Binzen/Germany and Ramsey/New Jersey. We offer clinical supplies management as well as storage and distribution of commercial products from our distribution hub in Lörrach/Germany.
InProcess-LSP
Network & Programme Sponsor
InProcess-LSP: Innovators in Process Analytical Technology Founded in 2014 and headquartered in Oss, the Netherlands, InProcess-LSP has positioned itself as a leading innovator in the field of Process Analytical Technology (PAT). Central to the company’s success is the NanoFlowSizer, a pioneering technology developed to address the complex challenges of nanoparticle characterization in dynamic systems. The NanoFlowSizer represents a significant advancement in nanoparticle measurement, utilizing a non-invasive optical approach for real-time size characterization. This unique instrumentation enables continuous, in-flow analysis of turbid nanosuspensions with unprecedented speed and accuracy, eliminating the need for sample preparation. Its ability to measure particle size and size distribution in highly concentrated and dynamic systems sets it apart in the field of nanoparticle analysis.
Nikon Europe B.V
Network & Programme Sponsor
Nikon BioImaging Labs provide contract research services for microscope-based imaging and analysis to the biotech, pharma, and larger research communities. Each lab's full-service capabilities include access to cutting-edge microscopy instrumentation and software, but also the services of expert biologists and microscopists, who are available to provide quality cell culture, sample preparation, data acquisition, and data analysis services. Hamamatsu Photonics products and technology include optical sensors, light sources, and systems that use these components. They are applied to various new technologies and devices to support people’s lives and help realize a more comfortable and prosperous society. Hamamatsu products are widely used for state-of-the-art medical equipment, test and inspection systems, microscopes that reveal the functions of cells, and giant telescopes that explore the mysteries of the universe.
Seppic S.A. - Établissement de Paris
Network & Programme Sponsor
Subsidiary of the Air Liquide Group since 1986, company of Air Liquide Healthcare, Seppic develops, manufactures and markets unique ingredients for cosmetic, nutraceutical, pharmaceutical, veterinary and industrial products. As expert in surfactants, polymers and formulation, Seppic offers pharmaceutical excipients adapted to oral, topical and parenteral routes of administration. Seppic’s parenteral excipients portfolio includes MONTANE™ PPI, a range of emulsifiers, and MONTANOX™ PPI, a range of solubilizers, providing formulators with high quality surfactants to ensure the most stable injectable formulations. Last year we launched MontanoxTM 20 HPB, our new non-ionic polysorbate with an improved formula dedicated to biological applications. Seppic surfactants comply with Good Manufacturing Practices (GMP Part II) and the current most important pharmacopoeias in the world (EP, USP-NF, JP/JPE and ChP), helping target multiple markets with one single range.
Start-Ups
InnoSyn B.V.
Start up - Therapeutic
InnoSyn offers a team of passionate & experienced problem solvers, applying innovative and cost-efficient technologies such as flow chemistry, bio- and chemocatalysis, to advance competitiveness of our customers across the (fine) chemical industries. Whether you are looking for i. a scalable route to produce your new chemical compound of interest, or ii. facing challenges on your cost of goods of your current products, or iii. looking for manufacturing capacity for your specific chemical product or enzyme, InnoSyn can deliver you the unique value creating solution based on our over 25 years of experience.
Congress Center Basel
MCH Swiss Exhibition (Basel) Ltd. Messeplatz 21, CH-4058 Basel
By Rail
Basel is an international rail hub with direct ICE, IC and EC connections to Germany, Austria, Italy, France and the Benelux countries. Messe Basel can be reached in five to ten minutes from the three railway stations in Basel: SBB (Switzerland), SNCF (France) (Frankreich) and DB (Badischer Bahnhof, Germany)
By Tram
From the SBB/SNCF railway station, it’s a ten-minute journey on the No. 1 or 2 Tram to the “Messeplatz/Exhibition Square” stop where Messe Basel and the Congress Center are located. From Badischer Bahnhof railway station, “Messeplatz/Exhibition Square” is the second stop on the No. 2 or 6 tram.
By Air
EuroAirport Basel-Mulhouse-Freiburg is 15 minutes by car from Messe Basel. Basel municipal transport’s No. 50 bus additionally provides a straightforward connection from the airport to the SBB/SNCF railway station. From there, tram No. 1 or 2 will take you directly to Messeplatz/Exhibition Square. From Zurich Airport a direct rail connection will bring you to the SBB/SNCF railway station in Basel in less than an hour. For further information including a map and full directions, please visit: https://www.messe-basel.com/en/about-us/getting-to-messe-basel/
By Car
Basel is located at the point where the Swiss, German and French motorway networks all meet. The exhibition and congress site has its own direct link to the A2 motorway. The “Messe” exit will take you straight to the Messe Basel car park with its 1,200 parking spaces.
Oxford Global has secured a number of bedrooms at the Basel Marriott Hotel at a reduced conference rate:
- Sunday 22nd June 2025 – £265 (Including Breakfast & City Tax)
- Monday 23rd June 2025 – £265 (Including Breakfast & City Tax)
*Please note: £30 supplement is applicable for double occupancy
Should you wish to book a room, please email help@oxfordglobal.com
The final cut-off date to book bedrooms is Monday 2nd June 2025 – any bookings after this date are subject to availability and rates. Please note that any cancellations within 14 days prior to arrival are subject to full cancellation charges.
We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.
As we continue to move forward with hosting our events in-person in 2025, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.
Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.
Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.
If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Discovery & Development Europe 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.
